AAv scleroprotein, production and use thereof

Details AAv scleroprotein, production and use thereof AAv scleroprotein, production and use thereof

2008-01-01

2008-01-01

Woitach, Joseph (Department: 1633)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S300000, C530S388220, C530S387900, C435S455000, C435S320100, C435S325000, C435S091400, C424S093200, C424S093100

Reexamination Certificate

active

07314912

ABSTRACT:
The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.

REFERENCES:
patent: 5276136 (1994-01-01), Skubitz et al.
patent: 6491907 (2002-12-01), Rabinowitz et al.
patent: 2001/0031463 (2001-10-01), Kleinschmidt et al.
patent: 2002/0192823 (2002-12-01), Bartlett
patent: WO 95/23867 (1995-09-01), None
patent: WO 96/00587 (1996-01-01), None
patent: WO 97/08298 (1997-03-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 99/67393 (1999-12-01), None
Kmiec, E. B. Gene Therapy. May-Jun. 1999. American Scientist, vol. 87, pp. 240-247.
Anderson, W.F, Human Gene Therapy. Apr. 1998. Nature, vol. 392, pp. 25-30.
Verma, I.M. and Somia, N. Gene Therapy- promises, problems and prospect. Sep. 1997. Nature, vol. 389, pp. 239-242.
Meng R.D. and El-Deiry, W.S. Tumor Suppressor Genes as Targets for Cancer Gene Therapy. 1999. Gene Therapy of Cancer,Chapter 1. pp. 3-18.
Buning et al, Receptor targeting of adeno-associated virus vectors, Gene Therapy (2003), vol. 10, pp. 1142-1151.
Smith and Zhang, The challenges of genome sequence annotation or “The devil is in the details”, Nature Biotechnology, (1997) vol. 15, pp. 1222-1223.
Tseng and Liang, Evolutionary model for predicting protein function by matching local surfaces: a Bayesian Monte Carlo approach, poster abstract downloaded Jun. 9, 2005.
Reid et al, Adeno-Associated Virus Capsids Displaying Immunoglobin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors, JVI, 2002, vol. 76, pp. 4559-4566.
Russell, S.J. Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects. 1994. European J. of Cancer vol. 30(A). pp. 1165-1171.
Bartlett et al., (1999), “Targeted Adeno-associated Virus Vector Transduction of Nonpermissive Cells Mediated By A Bispecific F (ab′γ)2Antibody,”Nat. Biotechnol., 17:181-186.
Cosset et al., (1996), “Targeting Retrovirus Entry,”Gene Ther., 3:946-956.
Douglas et al., (1996), “Targeted Gene Delivery By Tropism-modified Adenoviral Vectors,”Nat. Biotechnol., 14:1574-1578.
Girod et al., (1999), “Genetic Capsid Modifications Allow Efficient Re-targeting of Adeno-associated Virus Type 2,”Nature Medicine, 5:1052-1056.
Krasnykh et al., (1996), “Generation of recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism,”J. Virol., 70:6839-6846.
Ohno et al., (1997), “Cell-specific Targeting of Sindbis Virus Vectors Displaying IgG-binding Domains of Protein A,”Nat. Biotechnol., 15:763-767.
Ruffing et al., (1994), “Mutations in the Carboxy Terminus of Adeno-associated Virus 2 Capsid Proteins Affect Viral Infectivity: Lack of an RGD Integrin-binding Motif,”J. Gen. Virol., 75:3385-3392.
Steinbach et al., (1997), “Assembly of Adeno-associated Virus Type 2 Capsids In Vitro,”Biol. Abstr., 104, Ref. 46570.
Stevenson et al., (1997), “Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein,”J. Virol., 71:4782-4790.
Yang et al., (1998), “Development of Novel Cell Surface CD34-targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy,”Hum. Gene Ther., 9:1929-1937.
Wickham et al., (1996), “Adenovirus Targeted to Heparan-containing Receptors Increases its Gene Delivery Efficiency to Multiple Cell Types,”Nat. Biotechnol., 14:1570-1573.
Aumailley et al., “Identification of the Arg-Gly-Asp Sequence in Laminin A Chain as a Latent Cell-Binding Site Being Exposed in Fragment P1,”FEBS262:82-86 (1990).
Chapman et al., “Structure, Sequence, and Function Correlations Among Parvoviruses,”Virology194:491-508 (1993).
Chiorini et al., “High-Efficiency Transfer of the T Cell Co-Stimulatory Molecular B7-2 to Lymphoid Cells Using High-Titer Recombinant Adeno-Associated Virus Vectors,”Human Gene Therapy6:1531-1541 (1995).
Hermonat et al., “Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants,”Journal of Virology51:329-339 (1984).
Luo et al., “Preliminary X-Ray Crystallographic Analysis of Canine Parvovirus Crystals,”J. Mol. Biol.200:209-211 (1988).
Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector For Human Gene Therapy,”Human Gene Therapy5:793-801 (1994).
Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,”Current Topics in Microbiology and Immunology158:97-129 (1992).
Nimako et al., “Human Papillomavirus-Specific Cytotoxic T Lymphocytes in Patients with Cervical Intraepithelial Neoplasia Grade III,”Cancer Research57:4855-4861 (1997).
Ruffing et al., “Assembly of Viruslike Particles by Recombinant Structural Proteins of Adeno-Associated Virus Type 2 in Insect Cells,”Journal of Virology66:6922-6930 (1992).
Rutledge et al., “Infections Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2,”Journal of Virology72:309-319 (1998).
Srivastava et al., “Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome,”Journal of Virology45:555-564 (1983).
Tarpey et al., “Human Cytotoxic T Lymphocytes Stimulated by Endogenously Processed Human Papillomavirus Type 11 E7 Recognize a Peptide Containing a HLA-A2 (A*0201) Motif,”Immunology81:222-227 (1994).
Tsao et al., “The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications,”Science251:1456-1464 (1991).
Valsesia-Wittmann et al., Modifications in the Binding Domain of Avian Retrovirus Envelope Protein to Redirect the Host Range of Retroviral Vectors,Journal of Virology68:4609-4619 (1994).
Wickham et al., “Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins,”Journal of Virology71:8221-8229 (1997).
Wistuba et al., “Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly,”Journal of Virology71:1341-1352 (1997).
Wistuba et al., “Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins,”Journal of Virology69:5311-5319 (1995).
Wu et al., “The Canine Parvovirus Empty Capsid Structure,”J. Mol. Biol.233:231-244 (1993).
Shi et al., “Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors,”Human Gene Therapy12:1697-1711 (2001).
“Designer Gene Therapy May Target Specific Body Area,”Gene Therapy, Business News, Jan. 20, 2003. vol. 2, p. 1-8.
Marshall, “Second Child In French Trial is Found to Have Leukemia,”Science299:320 (2003).
Shi et al., “RGD Inclusion in VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism,”Molecular Therapy7:515-525 (2003).
Steinbach et al., “Assembly of Adeno-Associated Virus Type 2 Capsids in vitro,”Journal of General Virology78:1453-1462 (1997).
White et al., Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors,Circulation109:513-519 (2004).
Anderson, “Human Gene Therapy,”Nature392:25-30 (1998).
Asokan et al., “AAV Does the Shuffle,”Nature Biotechnology24:158-160 (2006).
Buning et al., “Receptor Targeting of Adeno-Associated Virus Vectors,”Gene Therapy10:1142-1151 (2003).
Grifman et al., “Incorporation fo Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids,”Molecular Therapy3:964-975 (2001).
Hoque et al., “Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation,”Journal of Virology73:7912-7915

Affiliated with

Also associated with

Rating

AAv scleroprotein, production and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with AAv scleroprotein, production and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and AAv scleroprotein, production and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811496